Pediatric Research of Charlottesville
Home
Our Studies
About Us
Contact Us
In The News
RSV Study Information
Pediatric Research of Charlottesville
Home
Our Studies
About Us
Contact Us
In The News
RSV Study Information
More
  • Home
  • Our Studies
  • About Us
  • Contact Us
  • In The News
  • RSV Study Information

  • Home
  • Our Studies
  • About Us
  • Contact Us
  • In The News
  • RSV Study Information

Currently Enrolling Studies

Pfizer Rimegepant Migraine Treatment

Primary Coordinator: Uyen Tran (Uyen@proc211.com)


Contact a study coordinator to learn more!


For more info:

https://clinicaltrials.gov/ct2/show/NCT04649242?recrs=ab&cond=Migraine&cntry=US&state=US%3AVA&city=Charlottesville&age=0&draw=2&rank=1

Pfizer Long-term Migraine Treatment

Contact a study coordinator to learn more!


Primary Coordinator: Uyen Tran (Uyen@proc211.com)


For more info:

https://clinicaltrials.gov/study/NCT04743141?id=C4951003&rank=1

Vaxcyte 31-Valent Pneumococcal Conjugate Vaccine

Primary Coordinator: Cathy Hansa (Catherine@proc211.com)


Contact a study coordinator to learn more!


For more info:

https://clinicaltrials.gov/study/NCT06720038?locStr=Charlottesville,%20VA&country=United%20States&state=Virginia&city=Charlottesville&cond=pneumococcal%2031&rank=2

Studies Currently in Follow Up

Pfizer 25-Valent Pneumococcal Conjugate Vaccine

Pfizer 25-Valent Pneumococcal Conjugate Vaccine

Pfizer 25-Valent Pneumococcal Conjugate Vaccine

Primary Coordinator: Uyen Tran (Uyen@proc211.com)


For more info:

https://www.pfizerclinicaltrials.com/nct06524414-pneumococcal-disease-trial

Sanofi RSV Vaccine for Infants and Toddlers

Pfizer 25-Valent Pneumococcal Conjugate Vaccine

Pfizer 25-Valent Pneumococcal Conjugate Vaccine

Primary Coordinator: Cathy Hansa (Catherine@proc211.com)


For more info:

https://clinicaltrials.gov/study/NCT06252285?cond=Respiratory%20Syncytial%20Virus&intr=Vaccine&term=Sanofi&rank=8


See our RSV study information tab for more information!

Enrolling Soon!

Pfizer Open label COVID-19 Vaccine In Children 5-11 Years of Age at High Risk for Severe COVID-19

Primary Coordinator: Uyen Tran (Uyen@proc211.com)


Pfizer BNT162B2 (LP.8.1)–Adapted Vaccine


For more info:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval

Copyright © 2025 Pediatric Research of Charlottesville, LLC - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept